Lena Jendeberg

Direktor/Vorstandsmitglied bei ATTANA AB

60 Jahre

Health Technology

Health Services

Consumer Services

Aktive Positionen von Lena Jendeberg

Unternehmen	Position	Beginn	Ende
ATTANA AB	Direktor/Vorstandsmitglied	01.01.2018	-

Unternehmen	Position	Beginn	Ende
Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	Corporate Officer/Principal	01.01.2016	-

Royal Institute of Technology

Doctorate Degree

International

Schweden

Operativ

Corporate Officer/Principal	1
Director/Board Member	1
Doctorate Degree	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
ATTANA AB	Health Services

Private Unternehmen	1
Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	Health Technology

Private Unternehmen

Health Technology